[LCID Study Number: 2016-056]
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
The primary objective of this study is to evaluate the objective response rate (ORR) of the study drug INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma that has fibroblast growth factor receptor (FGFR) 3 mutations or fusions.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-2734